Objective To analyze the efficacy and safety of Rh-endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer.Methods All 60 metastatic colorectal cancer patients were divided into the test group(n = 30) and the control group(n = 30). The control group was treated with chemotherapy regime FOLFOX4(Oxaliplatin + Fluorouracil + Calcium Levofolinate), the test group was treated by Endostar combined with FOLFOX4 scheme.Results The response rates were 53.3% in test group and 36.7% in control group respectively(P < 0.05), the disease control rate were 83.3% and 73.3%(P < 0.05). The median progression-free survival in test group and control group were 7.3 months versus 5.3 months(P < 0.05) and median overall survival were 11.6 months versus 9.3 months(P < 0.05). Among 27 cases of liver metastases were sub group analysis, difference on the test group and the control group response rate(RR) and disease control rate(DCR) had statistical significance(P < 0.05), but difference on progression free survival(PFS) and overall survival(OS) had no statistical significance(P > 0.05). The major toxicities were myelosuppression, gastrointestinal symptoms, neurotoxicity, most in grade I-II. After chemotherapy, quality of life(QOL) of patients were more improved than before treatment. After treatment the carcino embryonie antigen(CEA) and caner antigent 199(CA199) levels decreased obviously, furthermore, the test group decreased more obviously than the control group. Conclusion Rh-endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer is safer and effective, and also improves PFS. Objective To analyze the efficacy and safety of Rh-endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer. Methods All 60 metastatic colorectal cancer patients were divided into the test group (n = 30) and the control group (n = 30). The control group was treated with chemotherapy regime FOLFOX4 (Oxaliplatin + Fluorouracil + Calcium Levofolinate), the test group was treated by Endostar combined with FOLFOX4 scheme. Results The response rates were 53.3% in test group and 36.7% in control group respectively (P < (P <0.05). The median progression-free survival in test group and control group were 7.3 months versus 5.3 months (P <0.05) and median overall survival were 11.6 months versus 9.3 months (P <0.05). Among 27 cases of liver metastases were sub group analysis, difference on the test group and the control group response rate (RR) and disease control rate (DCR) had statistical significance (P <0.05), but diff The major toxicities were myelosuppression, gastrointestinal symptoms, neurotoxicity, most in grade I-II. After chemotherapy, quality of life (QOL After treatment of carcinoembryonic antigen (CEA) and caner antigent 199 (CA199) levels decreased obviously, furthermore, the test group decreased more obviously than the control group. Conclusion Rh-endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer is safer and effective, and also improves PFS.